IUGNF - Imugene welcomes positive FDA feedback on new manufacturing process for azer-cel

(NewsDirect)

Imugene Ltd (ASX:IMU)(OTCMKTS:IUGNF) MD Leslie Chong tells Proactive the company hasreceived positive FDA feedback on an improved manufacturing processfor azer-cel, an off the shelf CD19 CAR T cell therapy for bloodcancers. She says the improved manufacturing process allows forincreased robustness, consistency and scalability with a pivotal studypotentially to start in 2024. If approved, it’ll become the firstallogeneic CAR T cell therapy for cancer.

“Azer-cel has the potential to be the first CD19-directedallogeneic cell therapy and having the FDA support on themanufacturing process that can be used for the pivotal trial is anextremely important milestone for Imugene as it improves the overallrobustness and scalability of the product,” Chong said.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.